Everolimus NDC 70377-090

NDC codes

FDA NDC Directory

Product NDC (as listed)70377-090Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70377-0090Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70377-090-11	70377009011	28 TABLET, FOR SUSPENSION in 1 BOTTLE (70377-090-11)Marketed from Jan 14, 2026
70377-090-23	70377009023	4 BLISTER PACK in 1 CARTON (70377-090-23) / 7 TABLET, FOR SUSPENSION in 1 BLISTER PACKMarketed from Jan 14, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Everolimus
Generic name (nonproprietary): everolimus
Active ingredients: Everolimus — 2 mg/1
Dosage form: Tablet, For suspension
Route: Oral
Labeler: Biocon Pharma Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217216
Marketing start: Jan 14, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Decreased Immunologic Activity (Physiologic effect)Protein Kinase Inhibitors (Mechanism)mTOR Inhibitors (Mechanism)
Identifiers: Product ID 70377-090_7f7c486a-aefb-4798-aa9f-365799886a72SPL ID 7f7c486a-aefb-4798-aa9f-365799886a72SPL set ID 5b809dfe-c076-07c5-207e-178c3f0d32d3RxCUI 1308428, 1308430, 1308432UNII 9HW64Q8G6GUPC 0370377092114, 0370377090110, 0370377091117, 0370377091230, 0370377090233
Pharmacologic class: Kinase Inhibitor; mTOR Inhibitor Immunosuppressant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470377009011 followed by a unit qualifier and the quantity

Package 70377-0090-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 30, 2026.

Indications (excerpt from the label)

Everolimus tablets for oral suspension are kinase inhibitor indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) Everolimus tablets for oral suspension is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures. ( 1.6 ) 1.5 Tuberous Sclerosis Complex (TSC)-Associated Subependymal Giant Cell Astrocytoma (SEGA) Everolimus tablets for oral suspension are indicated in adult and pediatric patients aged 1 year and older with TSC f…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 217216

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217216
Product	Strength	Form · route	Labeler	Product NDC
Everolimus	Everolimus 3 mg/1	Tablet, For suspensionOral	Biocon Pharma Inc.	70377-091
Everolimus	Everolimus 5 mg/1	Tablet, For suspensionOral	Biocon Pharma Inc.	70377-092